Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma

Stefanius K, Ylitalo L, Tuomisto A, Kuivila R, Kantola T, Sirniö P, Karttunen T J & Mäkinen M J
(2011) Histopathology58, 679–692
Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma

[1]  A. Bardelli,et al.  Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer , 2009, Journal of the National Cancer Institute.

[2]  L. Mazzucchelli,et al.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Jass,et al.  Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon: classification, molecular genetics, natural history, and clinical management. , 2008, Gastroenterology clinics of North America.

[4]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[5]  M. O'brien,et al.  The serrated polyp pathway to colorectal carcinoma , 2008 .

[6]  M. O'brien.  Hyperplastic and serrated polyps of the colorectum. , 2007, Gastroenterology clinics of North America.

[7]  Emily J. Greenspan,et al.  Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans. , 2007, Cancer research.

[8]  M. Mäkinen,et al.  Colorectal serrated adenocarcinoma , 2007, Histopathology.

[9]  J. Jass.  Classification of colorectal cancer based on correlation of clinical, morphological and molecular features , 2007, Histopathology.

[10]  M. O'brien,et al.  Comparison of Microsatellite Instability, CpG Island Methylation Phenotype, BRAF and KRAS Status in Serrated Polyps and Traditional Adenomas Indicates Separate Pathways to Distinct Colorectal Carcinoma End Points , 2006, The American journal of surgical pathology.

[11]  Rozemary Karamatic,et al.  High prevalence of sessile serrated adenomas with BRAF mutations: a prospective study of patients undergoing colonoscopy. , 2006, Gastroenterology.

[12]  Shung-Haur Yang,et al.  Distinctive clinicopathological features of Ki‐ras mutated colorectal cancers , 2006, Journal of surgical oncology.

[13]  P. Laird,et al.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer , 2006, Nature Genetics.

[14]  Elizabeth L. Barry,et al.  K‐ras mutations in incident sporadic colorectal adenomas , 2006, Cancer.

[15]  A. Liakka,et al.  Morphology and microsatellite instability in sporadic serrated and non‐serrated colorectal cancer , 2005, The Journal of pathology.

[16]  Wei Zhao,et al.  BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. , 2003, Cancer research.

[17]  R. Goldbohm,et al.  K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. , 2003, Carcinogenesis.

[18]  D. Cooper,et al.  DNA alkylation and repair in the large bowel: animal and human studies. , 2002, The Journal of nutrition.

[19]  E. Sawyer,et al.  Molecular characteristics of serrated adenomas of the colorectum , 2002, Gut.

[20]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[21]  B. Leggett,et al.  Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. , 2001, The American journal of pathology.

[22]  D. Alberts,et al.  Ki-ras proto-oncogene mutations in sporadic colorectal adenomas: relationship to histologic and clinical characteristics. , 2001, Gastroenterology.

[23]  P. Vihko,et al.  Colorectal carcinoma associated with serrated adenoma – prevalence, histological features, and prognosis , 2001, The Journal of pathology.

[24]  M. Leppert,et al.  Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[25]  F. Bosman,et al.  p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. , 2000, European journal of cancer.

[26]  B. Leggett,et al.  Characterisation of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways. , 1999, Journal of clinical pathology.

[27]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[28]  A. Børresen-Dale,et al.  Ki-ras mutations and prognosis in colorectal cancer. , 1998, European journal of cancer.

[29]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[30]  T. P. Pretlow,et al.  Transgenic expression of human MGMT protects against azoxymethane-induced aberrant crypt foci and G to A mutations in the K-ras oncogene of mouse colon. , 1995, Carcinogenesis.

[31]  Joyce Bos.  ras oncogenes in human cancer: a review. , 1989, Cancer research.

[32]  Y. Nakamura,et al.  Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.

[33]  M. Millward,et al.  Promoter hypermethylation of the O(6)-methylguanine DNA methyltransferase gene and microsatellite instability in metastatic melanoma. , 2006, The Journal of investigative dermatology.

[34]  J. Eshleman,et al.  Detection of microsatellite instability. , 2001, Methods in molecular medicine.